Investment
Epsilogen Announces £3m Series A2 financing and licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London
Epsilogen Ltd (formerly known as IGEM Therapeutics), a global leader in the development of immunoglobulin E (IgE) antibodies to...